Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema

Doi: 10.36351/pjo.v36i3.1014

  • Hussain Ahmad Khaqan Associate Professor Ameer Ud Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
  • Usman Imtiaz Ameer Ud Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
  • Hasnain Muhammad Buksh Ameer Ud Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
  • Hafiz Ateeq Ur Rehman Ameer Ud Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
  • Raheela Naz Ameer Ud Din Medical College PGMI, Lahore General Hospital, Lahore, Pakistan
Keywords: Macular Edema, Aflibercept, Ziv-aflibercept, Bevacizumab, Diabetic Retinopathy, Wet Age related Macular degeneration, Retinal vein occlusion, intravitreal injection

Abstract

Purpose:  To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for the management of edema caused by different retinal pathologies.

Study Design:  Comparative interventional study.

Place and Duration of Study:  Lahore General Hospital, Lahore, from July 2018 to June 2019.

Material and Methods:  Patients with resistant, center involving macular edema due to diabetes, retinal vein occlusion and age related macular degeneration were recruited. Complete ocular examination was performed. All the patients were randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) and IVB (intravitreal bevacizumab). Each eye underwent intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab. Outcome was measured in terms of variation in central macular thickness (CMT) and also best corrected visual acuity (BCVA) at 3 months.

Results:  Total of 156 eyes of 136 patients completed whole duration of study and were included in the results. The mean baseline CMT was 510 μm (± 94 μm) in the IVB group and 493μm (±102 μm) in the IVZ group (P = 0.94). The mean baseline BCVA (log MAR) was 0.78 (Snellen's equivalent 6/36) in the IVZ and 0.70 (Snellen's equivalent 6/30) in the IVB group (P = 0.78). Central macular thickness was significantly reduced at 1st, 2nd and 3rd month in the IVZ group and IVB group (P < 0.001).

Conclusion:  Intravitreal Ziv-Aflibercept is safe and more effective than Bevacizumab for the treatment of edema caused by diabetes mellitus, retinal vein occlusion and wet age related macular degeneration.

Published
2020-05-04
How to Cite
1.
Khaqan HA, Imtiaz U, Buksh HM, Ur Rehman HA, Naz R. Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema. pjo [Internet]. 4May2020 [cited 2Jul.2020];36(3). Available from: http://pjo.org.pk/index.php/pjo/article/view/1014
Section
Original Article